An observational study in Autism Spectrum Disorder, sponsored by University Hospital, Montpellier. Recruiting at 2 sites in France. Open to participants aged 1 Year to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-10.
Sponsored by University Hospital, Montpellier · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Autism Spectrum Disorder by University Hospital, Montpellier — 5 open to participants now, 6 under way, none of them phase 3. Autism Spectrum Disorder · University Hospital, Montpellier.
Among the 12 studies in Autism Spectrum Disorder by University Hospital, Montpellier, this one is the only one that started in 2024, is one of 6 observational ones, and was the 12th registered.
1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.
Browse Autism Spectrum Disorder studies →5 of the 12 studies in Autism Spectrum Disorder by University Hospital, Montpellier are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 2–16
University Hospital, Montpellier · Sites in France
Ages 2–5
University Hospital, Montpellier · Sites in France
Healthy volunteers
University Hospital, Montpellier · Sites in France
Ages 6–16
By country, each count listing its studies:
Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.
This study: 1 Year to 16 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2024.
This study's planned enrollment of 600 is above the median of 103 across 323 observational studies indexed under Autism Spectrum Disorder.
Median enrollment 62 across the 6 interventional studies, 752 across the 6 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Montpellier is the lead sponsor of 1,264 studies on the registry; 226 are open to participants now.
1 of the studies in Autism Spectrum Disorder by University Hospital, Montpellier that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05512637University Hospital, MontpellierScreening for Neurodevelopmental Disorders in Siblings of Children With Autism Diagnosed in Tertiary Centers | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Autism Spectrum Disorder by University Hospital, Montpellier, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Autism Spectrum Disorder (ASD) is one of the neurodevelopmental disorders described in the DSM5 (American Psychiatric Association, 2013). This heterogeneous syndrome appears in childhood and persists throughout life with different developments from one individual to another. It is clinically characterized by the combination of deficits in social communication with restricted and repetitive behaviors. The prevalence of ASD has seen a significant increase over the last 10 years, with estimates varying greatly from one country to another, ranging from 4.2/1,000 in France to 31/1,000 in Iceland. In France, prevalence has been estimated by two child disability registers set up in the departments of Haute-Garonne (RHE31), Isère, Savoie, and Haute-Savoie (RHEOP), but there is no epidemiological surveillance system to estimate the national prevalence of ASD in the general population. However, the production of reliable epidemiological data at the national and territorial levels is essential for addressing the needs of individuals with ASD and for evaluating public policies.
The main objective of our project is to estimate the annual prevalence of ASD in children, adolescents, and young adults at the national and regional levels using medico-administrative databases (SNDS), to study its evolution over the period 2010-2019 and its geographical distribution in relation to socio-demographic indicators and healthcare accessibility. Our secondary objectives are to validate an algorithm for detecting ASD in the National Health Data System (SNDS) and to estimate the direct medical costs associated with ASD management.
The SNDS databases contain all medical care and treatments reimbursed for Health Insurance beneficiaries provided in the private or public sector. A case detection algorithm will be tested and validated on validation samples. Then, the prevalence of ASD will be estimated, taking into account geographical, socio-economic, and healthcare accessibility indicators, in order to study the factors associated with the significant disparity in rates observed in France and abroad. An estimate of direct medical costs will be made from the health insurance perspective.
Our project therefore proposes the development of reliable indicators on the management of ASD in France with the aim of providing useful indicators and tools for guiding health and disability policies in France, promoting the development of appropriate interventions, and thus contributing to the improvement of the care and support of individuals with ASD as well as reducing inequalities in access to healthcare for these vulnerable populations.
Population Study are children aged 16 or younger with ASD hospitalized in unversity hospital.
Inclusion Criteria:
ASD diagnostic code in healthcare database
≥ 1 hospitalization with ASD diagnostic code (F84\*)
Time frame: 1 year
Prevalence of ASD
Time frame: 2010-2019
Cost of medical care reimbursed by health insurance for patient with ASD
Time frame: 2010-2019
Start is estimated for Jun 2024; primary completion for Jan 2025, 7 months later.
Of 98 non-industry observational studies under Autism Spectrum Disorder, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 120. This study's planned 7 months is below that.
Counting every sponsor, half of 112 studies reached it within 40 months; a quarter within 26 and three quarters within 120.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Montpellier →